Early Discount Makes Rejection of Astellas’ Xtandi Too Difficult For NICE
This article was originally published in The Pink Sheet Daily
Executive Summary
By offering an early discount and providing clear clinical effectiveness evidence, Astellas Pharma has propelled its prostate cancer drug Xtandi through U.K.’s NICE.